Inactive Instrument

Newron Pharmaceuticals SpA Share Price CBOE EUROPE EQUITIES

Equities

0QOI

IT0004147952

Pharmaceuticals

End-of-day quote CBOE EUROPE EQUITIES
- CHF - Intraday chart for Newron Pharmaceuticals SpA

Financials

Sales 2024 * 35.98M 38.52M 35.12M 3.21B Sales 2025 * 25.95M 27.79M 25.33M 2.32B Capitalization 156M 167M 152M 13.94B
Net income 2024 * 7M 7.49M 6.83M 625M Net income 2025 * 4M 4.28M 3.9M 357M EV / Sales 2024 * 5.15 x
Net Debt 2024 * 29.11M 31.16M 28.42M 2.6B Net Debt 2025 * 2M 2.14M 1.95M 179M EV / Sales 2025 * 6.09 x
P/E ratio 2024 *
10.7 x
P/E ratio 2025 *
35.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.61%
More Fundamentals * Assessed data
Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients CI
Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member CI
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Newron Pharmaceuticals S.p.A., 2023 Earnings Call, Mar 19, 2024
Newron Pharmaceuticals' FY23 Loss Narrows; Revenue Up MT
Newron Pharmaceuticals S.p.A. Announces Agreement with the European Investment Bank to Extend the Near-Term Tranche Repayment Dates of Its 2018 Financing Agreement CI
Newron Pharmaceuticals Secures Extension on Three Loan Repayments MT
Newron Pharmaceuticals Investor Subscribes for Nearly EUR6 Million Shares MT
Swiss Equities Edge Higher as Markets Continue to Weigh Rate Cut Outlook MT
Transcript : Newron Pharmaceuticals S.p.A. - Special Call
Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia CI
Newron Pharmaceuticals' Schizophrenia Drug Lowers Disease Severity in Clinical Studies MT
Swiss Equities Rally as Economic Barometer Hits Eight-month High at Year-end MT
Newron Pharmaceuticals Completes Enrolment of Schizophrenia Patients for Evenamide Clinical Study MT
Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 15/12/15
Founder 63 01/98/01
Director of Finance/CFO - 01/02/01
Members of the board TitleAgeSince
Director/Board Member 78 01/08/01
Founder 63 01/98/01
Chairman 71 01/13/01
More insiders
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Calendar
More about the company